CDA | Evidence Driven
CDA | Evidence Driven

pembrolizumab

Details

Generic Name:
pembrolizumab
Project Status:
Received
Therapeutic Area:
Advanced or recurrent endometrial carcinoma
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0383-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma (EC), and then continued as monotherapy.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Pending
Indications:
Pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma (EC), and then continued as monotherapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open04-Oct-24
Call for patient/clinician input closed02-Dec-24
Submission received14-Nov-24
Submission accepted-
Last Updated : November 15, 2024